Botulism

Clinical Infectious Diseases

Volumn 41, Issue 8, 2005, Pages 1167-1173

  Sobel, Jeremy ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM ANTISERUM; BOTULINUM TOXIN;

ANAPHYLAXIS; ARTIFICIAL VENTILATION; BACTERIAL COLONIZATION; BOTULISM; CLINICAL FEATURE; CLOSTRIDIUM BOTULINUM; CRANIAL NERVE PARALYSIS; DEATH; DIAPHRAGM PARALYSIS; DIFFERENTIAL DIAGNOSIS; FLACCID PARALYSIS; FOOD CONTAMINATION; FOOD SAFETY; HUMAN; HYPERSENSITIVITY REACTION; IATROGENIC DISEASE; INFANT DISEASE; INTENSIVE CARE; PRIORITY JOURNAL; REVIEW; SERUM SICKNESS; SYMPTOM; TOXEMIA; WOUND INFECTION;

BOTULINUM ANTITOXIN; BOTULISM; CLOSTRIDIUM BOTULINUM; FOOD MICROBIOLOGY; HUMANS; INTENSIVE CARE;

EID: 26444527989     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/444507     Document Type: Review

References (55)

1. Shapiro R, Hatheway C, Becher J, Swerdlow DL. Botulism surveillance and emergency response: a public health strategy for a global challenge. JAMA 1997; 278:433-5.
2. Arnon SS, Schechter R, Inglesby TV, et al. Botulism toxin as a biological weapon: medical and public health management. JAMA 2001; 285: 1059-70.
3. Middlebrook JL, Franz DR. Botulinum toxins. In: Sidell FR, Takafuji TE, Franz DR, eds. Medical aspects of chemical and biological warfare. Washington, DC: Borden Institute, Walter Reed Army Medical Center, 1997:643-54.
4. Ekeus R. Report of the Secretary General on the status of the implementation of the Special Commission's plan for the ongoing monitoring and verification of Iraq's compliance with relevant parts of Sector C of Security Council Resolution 687. New York: United Nations Special Commission, 1991.
5. Cordesman A. Weapons of mass destruction in the Gulf and greater Middle East: force trends, strategy, tactics and damage effects. Washington DC: Center for Strategic and International Studies, 1998:18-52.
6. Bermudez J. The armed forces of North Korea. London: IB Tauris, 2001.
7. Tucker J. Toxic terror: assessing the terrorist use of chemical and biological weapons. Cambridge: MIT Press, 2000.
8. WuDunn S, Miller J, Broad WJ. How Japan germ terror alerted world. New York Times 26 May 1998:A1, A10
9. Hauschild. Clostridium botulinum. In: Doyle M, ed. Foodborne bacterial pathogens. New York: Marcel Dekker, 1989:112-89.
10. Hatheway CL. Clostridium botulinum and other clostridia that produce botulinum neurotoxin. In: Hauschild AHS, Dodds KL, eds. Clostridium botulinum: ecology and control in foods. New York: Marcel Dekker, 1992:3-20.
11. Hatheway CL. Clostridium botulinum. In: Bartlett JG, Blacklow NR, eds. Infectious diseases. Orlando: Saunders Company, 1991:1583-6.
12. Sugiyama H. Clostridium botulinum neurotoxin. Microbiol Rev 1980; 44:419-48.
13. Dack GM, Wood WL. Serum therapy of botulism in monkeys. J Infect Dis 1928; 42:209-12.
14. Ono T, Karashimada T, Iida H. Studies on the serum therapy of type E botulism (part III). Jpn J Med Sci Biol 1970; 28:177-91.
15. Morton HE. The toxicity of Clostridium botulinum type A toxin for various species of animals, including man. Philadelphia: The Institute for Cooperative Research, University of Pennsylvania, 1961.
16. Meyer K. The protective measures of the state of California against botulism. Am J Prev Med 1931; 5:261-93.
17. Centers for Disease Control and Prevention (CDC). Botulism in the United States, 1899-1996, handbook for epidemiologists, clinicians and laboratory workers. Atlanta, GA: CDC, 1998.
18. International Commission on Microbiological Specifications for Foods. Clostridium botulinum. In: Micro-organisms in foods 5: characteristics of microbial pathogens. New York: Blackie Academic & Professional, 1996:68-111.
19. Shapiro R, Hatheway CL, Swerdlow DL. Botulism in the United States: a clinical and epidemiologic review. Ann Intern Med 1998; 129.
20. Gangarosa EA. Botulism in the US, 1899-1969. Am J Epidemiol 1971; 93:93-101.
21. Wainright RB, Heyward WL, Middaugh JP, Hatheway CL, Harpster AP, Bender TR. Food-borne botulism in Alaska, 1947-1985: epidemiology and clinical findings. J Infect Dis 1988; 157:1158-62.
22. Sobel J, Tucker N, McLaughlin J, Maslanka S. Foodborne botulism in the United States, 1990-2000. Emerg Infect Dis 2004; 10:1605-11.
23. Werner SB, Passaro DJ, McGee J, Schechter R, Vugia DJ. Wound botulism in California, 1951-1998: a recent epidemic in heroin injectors. Clin Infect Dis 2000; 31:1018-24.
24. Passaro DJ, Werner SB, McGee J, MacKenzie W, Vugia D. Wound botulism associated with black tar heroin among injecting drug users. JAMA 1998; 279:859-63.
25. Arnon S. Infant botulism. In: Feigen RD, Cherry JD, eds. Textbook of pediatric infectious diseases, 4th ed. Philadelphia: WB Saunders, 1998: 1570-7.
26. Spika JS, Shafer N, Hargrett-Bean N. Risk factors for infant botulism in the United States. Am J Dis Child 1989; 143:828-32.
27. Long S. Epidemiologic study of infant botulism in Pennsylvania: report of the infant botulism study group. Pediatrics 1985; 75:928-34.
28. Arnon SS, Midura TF, Clay SA, Wood RM, Chin J. Infant botulism: epidemiological, clinical, and laboratory aspects. JAMA 1977; 237: 1946-51.
29. Chia JK, Clark JB, Ryan CA, Pollack M. Botulism in an adult associated with food-borne intestinal infection with Clostridium botulinum. N Engl J Med 1986; 315:239-54.
30. Arnon S. Botulism as an intestinal toxemia. In: Blaser MJ, Smith PD, Ravdin JI, Greenberg HB, Guerrant RL, ed. Infections of the gastrointestinal tract. New York: Raven Press, 1995:257-71.
31. Fenicia L, Franciosa G, Pourshaban M, Aureli P. Intestinal toxemia botulism in two young people, caused by Clostridium butyricum type E. Clin Infect Dis 1999; 29:1381-7.
32. Griffin PM, Hatheway CL, Rosenbaum RB, Sokolow R. Endogenous antibody production to botulinum toxin in an adult with intestinal colonization botulism and underlying Crohn's disease. J Infect Dis 1997; 175:633-7.
33. McCroskey L, Hatheway CL, Woodruff BA, Greenberg JA, Jurgenson P. Type F botulism due to neurotoxigenic Clostridium baratii from an unknown source in an adult. J Clin Microbiol 1991;29:2618-20.
34. Bakheit AM, Ward CD, McLellan DL. Generalized botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases [letter]. J Neurol Neurosurg Psychiatry 1997; 62: 198.
35. Hughes JM, Blumenthal JR, Merson MH, Lombard GL, Dowell VR, Gangarosa EJ. Clinical features of types A and B food-borne botulism. Ann Intern Med 1981; 95:442-5.
36. St. Louis ME, Peck SHS, Bowering D, et al. Botulism from chopped garlic: delayed recognition of a major outbreak. Ann Intern Med 1988; 108:363-8.
37. Franz DR, Pitt LM, Clayton MA, Hanes MA, Rose KJ. Efficacy of prophylactic and therapeutic administration of antitoxin for inhalation botulism. In: DasGupta BR, ed. Botulinum and tetanus neurotoxins. New York: Plenum Press, 1993:473-6.
38. Gunnison JB, Meyer KF. Susceptibility of monkeys, goats and small animals to oral administration of botulinum toxin types B, C, and D. J Infect Dis 1930; 46:335-40.
39. Herrero BA, Ecklund AE, Streett CS, Ford DF, King JK. Experimental botulism in monkeys-a clinical pathological study. Exp Mol Pathol 1967; 6:84-95.
40. Stookey JL, Street CS, Ford DF. Preliminary studies on the disappearance of botulinum toxin from the circulating blood of rhesus monkeys. Edgewood Arsenal, MD: US Army Edgewood Arsenal Chemical Research and Development Laboratories, 1965.
41. Oberst FW, Crook JW, Cresthull P, House MJ. Evaluation of botulism antitoxin, supportive therapy, and artificial respiration in monkeys with experimental botulism. Clin Pharmacol Ther 1968; 9:209-14.
42. Cherington M. Electrophysiologic methods as an aid in diagnosis of botulism: a review. Muscle Nerve 1982; 5:528-9.
43. Pascuzzi RM, Fleck JD. Acute peripheral neuropathy in adults: Guillain-Barre syndrome and related disorders. Neurol Clin 1997; 15: 529-47.
44. Asbury A. New concepts of Guillian-Barre syndrome. J Child Neurol 2000; 15:183-91.
45. Willison HJ, O'Hanlon GM. The immunopathogenesis of Miller Fisher syndrome. J Neuroimmunol 1999; 100:3-12.
46. Felz MW, Smith CD, Swift TR. A six-year-old girl with tick paralysis. N Engl J Med 2000; 342:90-4.
47. Woodruff BA, Griffin PM, McCroskey LM, et al. Clinical and laboratory comparison of botulism from toxin types A, B, and E in the United States, 1975-1988. J Infect Dis 1992; 166:1281-6.
48. Dowell VR Jr, McCroskey LM, Hatheway CL, Lombard GL, Hughes JM, Merson MH. Coproexamination for botulinal toxin and clostridium botulinum: a new procedure for laboratory diagnosis of botulism. JAMA 1977; 238:1829-32.
49. Tacket CO, Shandera WX, Mann JM, Hargrett NT, Blake PA. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med 1984; 76:794-8.
50. Chang GY, Ganguly G. Early antitoxin treatment in wound botulism results in better outcome. Eur Neurol 2003; 49:151-3.
51. Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med 1980; 69:567-70.
52. Hatheway CL, Snyder JD, Seals JE, Edell TA, Jewis GE Jr. Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E. J Infect Dis 1984; 150:407-12.
53. Kalluri P, Crowe C, Reller M, et al. An outbreak of botulism from food sold at a salvage store in Texas. Clin Infect Dis 2003; 37:1490-5.
54. Townes J, Cieslak PR, Hatheway CL, et al. An outbreak of type A botulism associated with a commercial cheese sauce. Ann Intern Med 1996; 125:558-63.
55. Angulo FJ, Getz J, Taylor JP, et al. A large outbreak of botulism: the hazardous baked potato. J Infect Dis 1998; 178:172-7.